Pharmaceutically acceptable phosphate-glycerol carrying bodies

Details for Australian Patent Application No. 2003201569 (hide)

Owner Vasogen Ireland Limited

Inventors Bolton, Anthony E; Mandel, Arkady

Agent Griffith Hack

Pub. Number AU-B-2003201569

PCT Number PCT/CA03/00065

PCT Pub. Number WO2003/061667

Priority 60/400,857 02.08.02 US; 60/351,427 28.01.02 US; 60/421,116 22.01.02 US; 60/364,620 18.03.02 US; 60/372,106 15.04.02 US; 2,368,656 21.01.02 CA

Filing date 21 January 2003

Wipo publication date 2 September 2003

Acceptance publication date 11 September 2008

International Classifications

A61K 31/683 (2006.01) - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols

A61K 9/127 (2006.01) Medicinal preparations characterised by special physical form - Liposomes

A61K 31/00 (2006.01)

A61K 31/164 (2006.01) - of a carboxylic acid with an aminoalcohol, e.g. ceramides

A61K 31/661 (2006.01) - Phosphorus acids or esters thereof not having PC bonds, e.g. fosfosal, dichlorvos, malathion

A61K 31/685 (2006.01)

A61K 31/688 (2006.01)

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 47/24 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen or sulfur

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 1/04 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/04 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/06 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/12 (2006.01) Drugs for disorders of the cardiovascular system

A61P 17/00 (2006.01) Drugs for dermatological disorders

A61P 17/02 (2006.01) Drugs for dermatological disorders

A61P 17/06 (2006.01) Drugs for dermatological disorders

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 21/00 (2006.01) Drugs for disorders of the muscular or neuromuscular system

A61P 21/04 (2006.01) Drugs for disorders of the muscular or neuromuscular system

Event Publications

3 April 2003 Complete Application Filed

  Priority application(s): 60/400,857 02.08.02 US; 60/351,427 28.01.02 US; 60/421,116 22.01.02 US; 60/364,620 18.03.02 US; 60/372,106 15.04.02 US; 2,368,656 21.01.02 CA

18 September 2003 Application Open to Public Inspection

  Published as AU-B-2003201569

15 June 2006 Amendment Made

  The nature of the amendment is: Amend the priority details from 10/051,381 22 Jan 2002 US to 60/421,116 22 Jan 2002 US 2003218843 The University of British Columbia The nature of the amendment is: Add the co-inventor Yang, Lu

11 September 2008 Application Accepted

  Published as AU-B-2003201569

15 January 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under reg. 22.2I(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003201570-PEPTIDE-CARRYING BODIES FOR IMMUNE RESPONSE

2003201568-PHOSPHOLIPID BODIES AND USE THEREOF IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES